Dr Reddy's Laboratories Ltd
NSE:DRREDDY

Watchlist Manager
Dr Reddy's Laboratories Ltd Logo
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Watchlist
Price: 1 350.9 INR 0.78% Market Closed
Market Cap: 1.1T INR
Have any thoughts about
Dr Reddy's Laboratories Ltd?
Write Note

Dr Reddy's Laboratories Ltd
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dr Reddy's Laboratories Ltd
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Liabilities
â‚ą159.8B
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Liabilities
â‚ą62.9B
CAGR 3-Years
-3%
CAGR 5-Years
-6%
CAGR 10-Years
4%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Liabilities
â‚ą190B
CAGR 3-Years
-1%
CAGR 5-Years
-3%
CAGR 10-Years
7%
Lupin Ltd
NSE:LUPIN
Total Liabilities
â‚ą97.1B
CAGR 3-Years
-3%
CAGR 5-Years
-9%
CAGR 10-Years
11%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Liabilities
â‚ą75.8B
CAGR 3-Years
1%
CAGR 5-Years
-3%
CAGR 10-Years
5%
M
Mankind Pharma Ltd
NSE:MANKIND
Total Liabilities
â‚ą26B
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Dr Reddy's Laboratories Ltd
Glance View

Market Cap
1.1T INR
Industry
Pharmaceuticals
Economic Moat
Narrow

In the bustling world of pharmaceuticals, Dr. Reddy's Laboratories Ltd. stands as a testament to innovation and resilience. Founded in 1984 by Dr. K. Anji Reddy, the company embarked on a journey to provide affordable and accessible medicine. Dr. Reddy's merged scientific rigor with a clear vision to eliminate health disparities worldwide. From creating complex generics and active pharmaceutical ingredients (APIs) to providing differentiated formulations, the company has built a strong foundation in both developed markets, like the United States and Europe, as well as in emerging markets such as India, Russia, and the CIS countries. This global footprint ensures that while many pharmaceutical companies are battling regulatory challenges and pricing pressures, Dr. Reddy's stays agile and competitive. The company's revenue streams primarily derive from its diverse portfolio of generic drugs, APIs, branded formulations, biologics, and proprietary products. Each sector is a strategic puzzle piece that enhances its market presence and ensures supply chain efficiency. Dr. Reddy's invests heavily in research and development to bolster its pipeline of future medications, aiming to address unmet medical needs and introduce value-added products. By leveraging strategic alliances and forging partnerships in development and distribution, the company adeptly navigates the complex landscape of the pharmaceutical industry, ensuring sustainable growth and reaffirming its commitment to affordable healthcare globally.

DRREDDY Intrinsic Value
621.53 INR
Overvaluation 54%
Intrinsic Value
Price

See Also

What is Dr Reddy's Laboratories Ltd's Total Liabilities?
Total Liabilities
159.8B INR

Based on the financial report for Sep 30, 2024, Dr Reddy's Laboratories Ltd's Total Liabilities amounts to 159.8B INR.

What is Dr Reddy's Laboratories Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
15%

Over the last year, the Total Liabilities growth was 72%. The average annual Total Liabilities growth rates for Dr Reddy's Laboratories Ltd have been 19% over the past three years , 15% over the past five years .

Back to Top